CTA+CDFI检查对脑动脉瘤诊断效能分析

Analysis of diagnostic efficacy of CTA+CDFI in cerebral aneurysm

目的 探究CT血管造影(CTA)+彩色多普勒血流显像(CDFI)检查对脑动脉瘤(CA)诊断效能。方法 选取2019年3月~2021年9月我院收治的221例疑似CA患者,均行CTA、CDFI检查,以三维数字减影血管造影(3D-DSA)检查为金标准,观察CTA、CDFI检查结果,分析两种检查方式单独及联合检查诊断效能,对比CTA、CDFI检查瘤体检出数量、具体瘤体部位符合率、瘤体最大直径、瘤颈径。结果 221例疑似CA患者中,3D-DSA检查显示阳性134例,CDFI检查显示阳性122例,CTA检查显示阳性124例,CTA+CDFI检查显示阳性140例。CTA+CDFI检查灵敏度(97.76%)、准确度(94.57%)、阴性预测值(96.30%)高于CDFI(85.07%、87.33%、79.80%)、CTA(85.82%、87.33%、80.41%)单独检查(P<0.05);CTA+CDFI检查漏诊率(2.24%)低于CDFI(14.93%)、CTA(14.18%)单独检查(P<0.05);CTA+CDFI检查与3D-DSA检查金标准CA瘤体最大直径、瘤颈径对比无显著差异(P>0.05)。结论 CTA+CDFI检查应用于CA诊断中,其诊断效能显著高于CTA检查、CDFI检查单一诊断,可提高瘤体检出率及病灶部位符合率,有利于临床针对性制定治疗方案,改善CA患者预后。

Objective To explore the diagnostic efficacy of CT angiography(CTA)and color Doppler flow imaging(CDFI)in cerebral aneurysm(CA).Methods 221 patients with suspected CA admitted to our hospital from March 2019 to September 2021 were selected.CTA and CDFI were per⁃formed.Three⁃dimensional digital subtraction angiography(3D⁃DSA)was used as the gold standard.The results of CTA and CDFI were observed,and the diagnostic efficacy of the two methods were analyzed.The number of tumors detected by CTA and CDFI,the coincidence rate of specific tumor location,the maximum diameter of tumor body and the diameter of tumor neck were compared.Results Among 221 suspected CA patients,134 cases were positive by 3D⁃DSA,122 cases by CDFI,124 cases by CTA and 140 cases by CTA+CDFI.The sensitivity(97.76%),accuracy(94.57%)and negative predictive value(96.30%)of CTA+CDFI were higher than those of CDFI(85.07%,87.33%,79.80%),CTA(85.82%,87.33%,80.41%)alone(P<0.05);The miss diagnosis rate of CTA+CDFI(2.24%)was lower than that of CDFI(14.93%)and CTA(14.18%)(P<0.05);There was no significant difference between CTA+CDFI and 3D⁃DSA(P>0.05).Conclusion the diagnostic efficacy of CTA+CDFI in the diagnosis of Ca is significantly higher than that of CTA and CDFI alone,which can improve the rate of tumor detection and the coincidence rate of lesion location,and is conducive to the development of clinical targeted treat⁃ment and the improvement of the prognosis of CA patients.